Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1093/femspd/ftaa036

http://scihub22266oqcxt.onion/10.1093/femspd/ftaa036
suck pdf from google scholar
32667665!7454646!32667665
unlimited free pdf from europmc32667665    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32667665  :  Publisher

suck abstract from ncbi

pmid32667665
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19) #MMPMID32667665
  • Jia Z; Song X; Shi J; Wang W; He K
  • Pathog Dis 2020[Jun]; 78 (4): ä PMID32667665show ga
  • The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world has led to a pandemic with high morbidity and mortality. However, there are no effective drugs to prevent and treat the disease. Transcriptome-based drug repositioning, identifying new indications for old drugs, is a powerful tool for drug development. Using bronchoalveolar lavage fluid transcriptome data of COVID-19 patients, we found that the endocytosis and lysosome pathways are highly involved in the disease and that the regulation of genes involved in neutrophil degranulation was disrupted, suggesting an intense battle between SARS-CoV-2 and humans. Furthermore, we implemented a coexpression drug repositioning analysis, cogena, and identified two antiviral drugs (saquinavir and ribavirin) and several other candidate drugs (such as dinoprost, dipivefrine, dexamethasone and (-)-isoprenaline). Notably, the two antiviral drugs have also previously been identified using molecular docking methods, and ribavirin is a recommended drug in the diagnosis and treatment protocol for COVID pneumonia (trial version 5-7) published by the National Health Commission of the P.R. of China. Our study demonstrates the value of the cogena-based drug repositioning method for emerging infectious diseases, improves our understanding of SARS-CoV-2-induced disease, and provides potential drugs for the prevention and treatment of COVID-19 pneumonia.
  • |*Drug Repositioning[MESH]
  • |Antiviral Agents/*pharmacology[MESH]
  • |Betacoronavirus/*drug effects[MESH]
  • |Bronchoalveolar Lavage Fluid/chemistry[MESH]
  • |COVID-19[MESH]
  • |Cell Degranulation/immunology[MESH]
  • |Coronavirus Infections/*drug therapy[MESH]
  • |Endocytosis/immunology[MESH]
  • |Gene Expression Profiling[MESH]
  • |Humans[MESH]
  • |Lysosomes/immunology[MESH]
  • |Molecular Docking Simulation[MESH]
  • |Neutrophil Activation/immunology[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy[MESH]
  • |Ribavirin/*pharmacology[MESH]
  • |SARS-CoV-2[MESH]
  • |Saquinavir/*pharmacology[MESH]
  • |Transcriptome[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    ä 4.78 2020